

**Supplemental Table 1: Treatment and Genetic information**

Protocol	Diagnosis	Treatments	mutation*	alleles in gnomAD
Barcelona	PAPA	GC (PO+IA), canakinumab	PSTPIP1: p.Glu250Gln	0
Barcelona	PAPA	GC (PO), methotrexate	PSTPIP1: p.Glu250Gln	0
Barcelona	PAPA	GC (PO), methotrexate	PSTPIP1: p.Glu250Gln	0
Barcelona	PAPA	GC (PO+IA), anakinra	PSTPIP1: p.Ala230Thr	0
NHGRI	PAPA	GC(IV+PO), anakinra, canakinumab, infliximab, golimumab, certolizumab	PSTPIP1: p.Ala230Thr	0
NHGRI	PAPA	GC(PO+IV), anakinra, golimumab, canakinumab	PSTPIP1: p.Glu250Gln	0
NIAID	PAPA	GC(IV+PO), golimumab, canakinumab	PSTPIP1: p.Glu250Gln	0
NHGRI	PAPA	anakinra, canakinumab, infliximab,	PSTPIP1: p.Ala230Thr	0
NHGRI	PAPA / Hz/Hc	GC(PO+IV), anakinra, golimumab, bone marrow transplant	PSTPIP1: p.Glu257Lys	0
NHGRI	PAPA	GC(PO+IV), golimumab, anakinra	PSTPIP1: p.Ala230Thr	0
NHGRI	PAPA	anakinra	PSTPIP1: p.Ala230Thr	0
NHGRI	PAPA	anakinra	PSTPIP1: p.Ala230Thr	0
NHGRI	PAPA	GC(PO), infliximab	PSTPIP1: p.Ala230Thr	0
NHGRI	PAPA	canakinumab, adalimumab	PSTPIP1: p.Ala230Thr	0
NHGRI	PAPA	GC(IV+PO), anakinra, canakinumab, golimumab, ruxolitinib	PSTPIP1: p.Glu257Gly	0
NHGRI	PAPA	GC(PO), anakinra	PSTPIP1: p.Ala230Thr	0
NHGRI	PAPA	golimumab, anakinra	PSTPIP1: p.Ala230Thr	0
NHGRI	PAPA / Hz/Hc	rilonacept	PSTPIP1: p.Glu250Lys	0
NIAID	PAPA	GC(PO+IV), anakinra, canakinumab, rilonacept, tocilizumab	PSTPIP1: p.Glu250Gln	0
NHGRI	PAPA-like	GC(PO), golimumab	PSTPIP1: p.Arg405Cys	158
NHGRI	PAPA-like	GC(PO), golimumab	none	
NHGRI	PAPA-like	GC(IV+PO), anakinra, golimumab, canakinumab	none	
NHGRI	PAPA-like	GC(PO), adalimumab, anakinra	none	
NHGRI	PAPA-like	anakinra, cyclosporine	none	
NHGRI	PAPA-like	golimumab, anakinra, ustekinumab	none	
NHGRI	PAPA-like	anakinra, infliximab, ustekinumab	none	
NHGRI	PAPA-like	GC(PO+IV), secukinumab, canakinumab	none	
NHGRI	PAPA-like	GC(PO), anakinra, golimumab, ustekinumab	none	
NHGRI	PAPA-like	adalimumab, doxycycline	none	
NHGRI	Undifferentiated	anakinra	PSTPIP1: p.Gly258Ala	2415
NHGRI	FMF	colchicine	MEFV: p.Val726Ala/Lys695Arg	561/1648
NHGRI	FMF	colchicine	MEFV: p.Val726Ala/Met694Ile	561/36
NHGRI	FMF	colchicine, anakinra	MEFV: p.Met694Val/Met694Val	77/77
NHGRI	FMF	anakinra	MEFV: p.Val726Ala/Glu148Gln	561/17464
NHGRI	FMF	colchicine	MEFV: p.Met694Val/Glu148Gln	77/17464
NHGRI	FMF	colchicine, anakinra	MEFV: p.Arg761His/Arg761His	58/58
Pitt	FMF	GC(IV+PO), colchicine, anakinra	MEFV: p.Met694Val/Met694Val	77/77
Pitt	NLRC4-MAS	GC(IV+PO), anakinra	NLRC4: p.Gln657Leu	0
NIAID	NLRC4-MAS	GC(IV+PO), anakinra, canakinumab	NLRC4: p.Thr337Ser	0
NIAID	NLRC4-MAS	GC(IV+PO), anakinra	NLRC4: p.Val341Ala	0

\*All *PSTPIP1* and *NLRC4* mutations appeared in heterozygosity. GC=glucocorticoids. PAPA=Pyogenic Arthritis, Pyoderma, Acne; Hz/Hc=Hyperzincemia/hypercalprotectinemia syndrome.